<DOC>
	<DOCNO>NCT00003166</DOCNO>
	<brief_summary>This phase I trial study side effect best dose bryostatin-1 give together vincristine treat patient chronic lymphocytic leukemia , non-Hodgkin 's lymphoma , multiple myeloma . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell</brief_summary>
	<brief_title>Bryostatin Vincristine B-Cell Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose bryostatin 1 24 hour infusion vincristine administer sequentially . II . To determine effect combination program cell death ( apoptosis ) . III . To determine immunomodulatory effect bryostatin 1 . IV . To observe patient clinical antitumor response give combination bryostatin 1 vincristine . OUTLINE : This dose-escalation study bryostatin 1 . Patients receive bryostatin 1 IV 24 hour follow immediately vincristine IV . Treatment repeat every 2 week absence disease progression unacceptable toxicity . Patients complete 6 course therapy may receive subsequent course every 3 week every 4 week 24 month treatment . Patients may return 2- 3-week treatment course discretion principal investigator . Cohorts 3 patient receive escalate dos bryostatin 1 maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 1 3 patient experience dose-limiting toxicity . Patients follow every 3 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<criteria>Patients biopsy proven Bcell malignancy [ e.g . chronic lymphocytic leukemia ( CLL ) , nonHodgkin 's lymphoma ( NHL ) , multiple myeloma ( MM ) ] ; HIVassociated lymphomas acute leukemia eligible Performance status : ECOG 0 , 1 , 2 Life expectancy least 12 week Patients aggressive NHL enrol fail possible therapy curative intent Patients CLL must fail alkylating agentcontaining regimen well fludarabine chemotherapy Patients multiple myeloma must receive least one prior chemotherapy regimen eligible dose intensification treatment approach At least 4 week must elapse since prior largefield radiation therapy Patients must previous anticancer therapy least 3 week ( 6 week BCNU mitomycin C ) recover treatment related toxicity Prior vincristine therapy allow Sexually active men woman must use accepted effective method contraception In woman childbearing age , pregnancy test may do discretion investigator Must give write informed consent Patients brain metastasis , leptomeningeal involvement , primary CNS NHL , acute leukemia ineligible Patients HIV infection ineligible WBC &lt; 3000/ul Granulocytes &lt; 1500/ul Platelets &lt; 50,000/ul Hemoglobin = &lt; 8.5 g/dl Bilirubin &gt; 1.5 mg/dl AST ALT &gt; 2 time normal Creatinine &gt; 2.0 mg/dl , and/or actual creatinine clearance &lt; 40 ml/min/1.73 m^2 ; patient require 24 hr creatinine clearance Clinical evidence bleed diathesis ECOG Performance status 3 4 Patients pregnant lactating ; vincristine cause fetal harm Patients clinically apparent neuropathy ineligible ( &gt; = grade 2 neuropathy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>